

b.) Amendment to the Claims

1. (Currently Amended) A recombinant antibody or an antibody fragment thereof, which specifically binds to human insulin-like growth factor-I (IGF-I) and human insulin-like growth factor-II (IGF-II) to inhibit ~~an activity to control of~~ proliferation, differentiation ~~and/or~~ or apoptosis of epithelial cells of both human IGF-I and human IGF-II and ~~can bind to both human IGF I and human IGF II with equivalent strength of affinity~~, wherein the VH of the recombinant antibody or the antibody fragment thereof comprises an amino acid sequence consisting of SEQ ID NO:26 and the VL comprises an amino acid sequence consisting of SEQ ID NO:27, 28 or 29.

Claims 2-16 (Cancelled).

17. (Previously Presented) The recombinant antibody or the antibody fragment thereof according to Claim 1, wherein the VL comprises an amino acid sequence consisting of SEQ ID NO:27.

18. (Previously Presented) The recombinant antibody or the antibody fragment thereof according to Claim 1, wherein the VL comprises an amino acid sequence consisting of SEQ ID NO:28.

19. (Previously Presented) The recombinant antibody or the antibody fragment thereof according to Claim 1, wherein the VL comprises an amino acid sequence consisting of SEQ ID NO:29.

20. (Previously Presented) The recombinant antibody or the antibody fragment thereof according to any one of Claims 1 or 17-19, wherein the recombinant antibody is a human CDR-grafted antibody.

21. (Currently Amended) The recombinant antibody or the antibody fragment thereof according to any one of Claims 1 or 17-19, wherein the antibody fragment is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')₂, single-stranded antibody (scFv), dimerized variable region (diabody), disulfide-stabilized variable region (dsFv), and CDR-containing peptide.

Claims 22-24 (Cancelled).

25. (Withdrawn and Currently Amended) A process for producing a recombinant antibody or the antibody fragment thereof according to any one of claims 1 or 17-19, which comprises a step of culturing a transformant obtained by introducing into a host cell an expression vector carrying DNA encoding said recombinant antibody or

antibody, fragment antibody fragment thereof in a medium to produce the recombinant antibody or the antibody fragment thereof in a culture, and isolating and purifying the recombinant antibody or the antibody fragment thereof from the culture.

26. (Withdrawn and Previously Presented) A medicament which comprises the recombinant antibody or the antibody fragment thereof according to any one of claims 1 or 17-19 as an active ingredient.

27. (Withdrawn and Previously Presented) A method for treating IGF-associated diseases, which comprises administering a therapeutically effective amount of the recombinant antibody or the antibody fragment thereof according to any one of claims 1 or 17-19 to a patient in need thereof.

28. (Withdrawn and Previously Presented) A method according to any one of claims 1 or 17-19, wherein the IGF-associated diseases are selected from the group consisting of cancer, acromegaly and diabetic complications.

Claims 29 and 30 (Cancelled).

31. (Currently Amended) The recombinant antibody or the antibody fragment thereof according to Claim 20, wherein the antibody fragment is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')₂, single-stranded antibody (scFv), dimerized variable region (diabody), disulfide-stabilized variable region (dsFv), and CDR-containing peptide.